Sign in
Enrolling by invitationNo phase

RNA Markers to Help Detect Endometriosis Early

Looks for gene signals that may help detect endometriosis in women of reproductive age.

Key facts

Who runs it
Wren Laboratories LLC
Where
Branford and Farmington, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Registry title
RNA Assays for Endometriosis Detection and Diagnosis
Status
Enrolling by invitation
People taking part
400 people, planned
Started
1 Jan 2024
Expected to end
31 Dec 2028
Type of study
Observational, 2 groups
Treatments tested
  • EndoDx
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 20 to 35 to test a blood-based RNA marker for endometriosis. It enrols women with endometriosis and healthy control women.

Age
20 to 35 years
Sex
Women only
Disease stage
Women with endometriosis and a history of infertility of more than 1 year, plus a control group without systemic disease.
Biomarker or test result
The study looks at RNA gene markers (mRNA) to help diagnose endometriosis.

Main reasons for not taking part

  • Polycystic ovary syndrome or hyperprolactinemia (endometriosis group)
  • Severe heart and blood vessel, liver, kidney or blood-forming system disease (endometriosis group)
  • Autoimmune disease (endometriosis group)
  • Uterine fibroids, endometritis, non-vegetative ovarian cysts, ovarian cancer or internal genital tuberculosis (endometriosis group)
  • Gynaecological cancer or genital tuberculosis (control group)

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • For the endometriosis cohort
  • a history of infertility more than 1 year
  • age 20-35 years
  • normal liver and kidney function, without gynaecological and other systemic disease
  • -

Who cannot take part

  • polycystic ovary syndrome, hyperprolactinemia
  • severe cardiovascular system, liver, kidney, and hematopoietic system disease
  • autoimmune disease
  • uterine fibroids, endometritis, non-vegetative ovarian cysts, ovarian malignancies, and internal genital tuberculosis
  • For the endometriosis cohort
  • -

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 35 years old?

Where in United States

Also in 1 other country, 1 site

  • Wren LaboratoriesBranford, United StatesEnrolling by invitation
  • Charlotte Johnson Hollfelder Center for Women's HealthFarmington, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery. A key unmet need therefore is an accurate biomarker that can be used to detect the disease early. This study is a prospective trial to identify candidate mRNA-markers which can be used to aid in the diagnosis of this disease. It is a discovery/validation study that will identify and confirm a gene expression panel that is specific for endometriosis and provides a non-invasive tool for future use.

The 2 groups in the trial

  • Endometriosis

    Women with suspected endometriosis undergoing laparoscopy to provide tissue for pathological diagnosis of the disease.

    Treatment: EndoDx

  • Control

    Women undergoing surgery for benign cervical disease.

    Treatment: EndoDx

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development and Evaluation of RNA-based Markers for Detecting and Diagnosing Endometriosis
Plain-language title
RNA Markers to Help Detect Endometriosis EarlyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06907303, who can take part
Record updated
12 November 2026